Genome-guided discovery of cancer therapeutic targets
Prathyusha Konda,
Simon Garinet,
Eliezer M. Van Allen,
Srinivas R. Viswanathan
Affiliations
Prathyusha Konda
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Simon Garinet
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Eliezer M. Van Allen
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Srinivas R. Viswanathan
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Corresponding author
Summary: The success of precision oncology—which aims to match the right therapies to the right patients based on molecular status—is predicated on a robust pipeline of molecular targets against which therapies can be developed. Recent advances in genomics and functional genetics have enabled the unbiased discovery of novel molecular targets at scale. We summarize the promise and challenges in integrating genomic and functional genetic landscapes of cancer to establish the next generation of cancer targets.
